# US 11,993,639 B2 · Therapeutic IL-13 polypeptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,993,639 B2
- Document ID: US11993639B2
- Status: Granted
- Kind: B2
- Application number: 17/388,895
- Filed: 2021-07-29
- Published: 2021-12-02
- Granted: 2024-05-28
- Earliest claimed: 2012-01-27
- Assignees: The Board of Trustees of the Leland Stanford Junior University
- Applicants: The Board of Trustees of the Leland Stanford Junior University
- Inventors: Kenan Christopher Garcia; Ignacio Moraga Gonzalez
- Web page: https://patentgrep.com/patent/US11993639B2

## CPC

- C07K 14/5437: {IL-13}
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- G09G 3/2003: {Display of colours (specific for liquid crystal displays G09G3/3607)}
- G09G 3/2074: {using sub-pixels}
- H04N 19/176: the region being a block, e.g. a macroblock
- H04N 19/182: the unit being a pixel
- A61K 38/2086: {IL-13 to IL-16}
- C07K 2319/00: Fusion polypeptide
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- G09G 2320/0247: Flicker reduction other than flicker reduction circuits used for single beam cathode-ray tubes
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G09G: ARRANGEMENTS OR CIRCUITS FOR CONTROL OF INDICATING DEVICES USING STATIC MEANS TO PRESENT VARIABLE INFORMATION (arrangements for transferring data between digital computers and displays G06F3/14; static indicating arrangements comprising an association of a number of separate sources or light control cells G09F9/00; static indicating arrangements comprising integral associations of a number of light sources H01J, H01K, H10H, H05B33/12; scanning, transmission or reproduction of documents or the like, e.g. facsimile transmission, details thereof H04N1/00)
- H04N: PICTORIAL COMMUNICATION, e.g. TELEVISION
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Variant IL-13 polypeptides are provided, which are engineered to have one or more of the following properties: (a) altered affinity for IL-13Rα2, relative to the native human IL-13 protein; (b) altered affinity for IL-13Rα1 relative to the native human IL-13 protein; (c) a disruption in the binding site for IL-4Rα relative to the native human IL-13 protein.

## Claims

### Claim 1

A nucleic acid encoding a polypeptide, wherein the polypeptide comprises a modified interleukin 13 (IL-13) polypeptide engineered to have (a) increased affinity for interleukin 13 receptor α2 (IL-13Rα2) relative to native human IL-13 protein; and (b) decreased affinity for interleukin 13 receptor α1 (IL-13Rα1) relative to native human IL-13 protein; wherein the modified IL-13 polypeptide comprises amino acid changes L10H, R86T, D87G, T88R, R108K relative to wild type IL-13.

### Claim 2 (depends on 1)

The nucleic acid according to claim 1, wherein the modified IL-13 polypeptide comprises an amino acid sequence set forth in SEQ ID NO: 18.

### Claim 3 (depends on 1)

The nucleic acid of claim 1, further comprising an additional nucleic acid sequence encoding a heterologous polypeptide, wherein the nucleic acid sequence comprises the additional nucleic acid sequence that encodes the heterologous polypeptide fused to the modified IL-13 polypeptide.

### Claim 4 (depends on 3)

The nucleic acid of claim 3, wherein the heterologous polypeptide comprises an IgG Fc region.

### Claim 5 (depends on 3)

The nucleic acid of claim 3, wherein the heterologous polypeptide comprises a polypeptide capable of increasing half-life of the modified IL-13 polypeptide in vivo.

### Claim 6 (depends on 1)

A vector comprising the nucleic acid according to claim 1.

### Claim 7 (depends on 1)

A host cell comprising the nucleic acid according to claim 1.

### Claim 8 (depends on 6)

A host cell comprising the vector of claim 6.